Company Overview

Introduction

This page provides an overview of companies developing treatments for neurodegenerative diseases, including pharmaceutical companies, biotechnology firms, and medical device companies. [@pharma2024]

Major Pharmaceutical Companies

Large Pharma (Alzheimer's)

| Company | Pipeline Focus | Key Programs | Market Position | [@business2024]
|---------|----------------|--------------|-----------------| [@clinicaltrialsgov2024]
| Eli Lilly | Amyloid, [Tau](/proteins/tau) | [Donanemab](/entities/donanemab), Remternetug | Leader |
| Biogen | Amyloid | Leqembi, BIIB080 | Leader |
| Roche | Amyloid, Tau | Gantenerumab, Semorinemab | Strong |
| Eisai | Amyloid | Leqembi, Elenbecestat | Strong |
| Janssen | Tau | JNJ-63733657 | Growing |

Large Pharma (Parkinson's)

| Company | Pipeline Focus | Key Programs | Market Position |
|---------|----------------|--------------|-----------------|
| AbbVie | Motor complications | ABBV-951 | Leader |
| Novartis | [Alpha-synuclein](/proteins/alpha-synuclein) | Cinpanemab | Strong |
| Roche | Alpha-synuclein | Prasinezumab | Strong |
| UCB | Alpha-synuclein | Lixisenatide | Growing |

Biotechnology Companies

Alzheimer's Focus

Introduction

This page provides an overview of companies developing treatments for neurodegenerative diseases, including pharmaceutical companies, biotechnology firms, and medical device companies. [@pharma2024]

Major Pharmaceutical Companies

Large Pharma (Alzheimer's)

| Company | Pipeline Focus | Key Programs | Market Position | [@business2024]
|---------|----------------|--------------|-----------------| [@clinicaltrialsgov2024]
| Eli Lilly | Amyloid, [Tau](/proteins/tau) | [Donanemab](/entities/donanemab), Remternetug | Leader |
| Biogen | Amyloid | Leqembi, BIIB080 | Leader |
| Roche | Amyloid, Tau | Gantenerumab, Semorinemab | Strong |
| Eisai | Amyloid | Leqembi, Elenbecestat | Strong |
| Janssen | Tau | JNJ-63733657 | Growing |

Large Pharma (Parkinson's)

| Company | Pipeline Focus | Key Programs | Market Position |
|---------|----------------|--------------|-----------------|
| AbbVie | Motor complications | ABBV-951 | Leader |
| Novartis | [Alpha-synuclein](/proteins/alpha-synuclein) | Cinpanemab | Strong |
| Roche | Alpha-synuclein | Prasinezumab | Strong |
| UCB | Alpha-synuclein | Lixisenatide | Growing |

Biotechnology Companies

Alzheimer's Focus

| Company | Approach | Stage | Notable |
|---------|----------|-------|---------|
| Prothelia | Tau biology | Preclinical | Novel target |
| AC Immune | Tau immunotherapy | Phase 2 |ACI-35|
| Alzheon | Amyloid aggregation | Phase 3 |ALZ-801|
| Ariana | Immunotherapy | Phase 1 | Novel antibodies |
| Vigil Neuroscience | [TREM2](/proteins/trem2) agonist | Preclinical | [Microglia](/cell-types/microglia-neuroinflammation) targeting |

Parkinson's Focus

| Company | Approach | Stage | Notable |
|---------|----------|-------|---------|
| Prevail Therapeutics | Gene therapy | Phase 1/2 | PR001 |
| Voyager Therapeutics | Gene therapy | Phase 1 | VY-AADC |
| Inhibikase | Alpha-synuclein | Phase 1 | IkT-148009 |
| Neuraly | Alpha-synuclein | Phase 2 | NLY01 |

ALS Focus

| Company | Approach | Stage | Notable |
|---------|----------|-------|---------|
| Amylyx | Neuroprotection | Approved | AMX0035 |
| Cytokinetics | Muscle function | Phase 3 | Reldesomt |
| Clene | Energy metabolism | Phase 2 | CNM-Au8 |
| QurAlis | ALS genetics | Preclinical | Precision medicine |

Medical Device Companies

Deep Brain Stimulation

| Company | Products | Innovation |
|---------|----------|------------|
| Medtronic | Percept PC, Activa | Directional leads |
| Boston Scientific | Vercise | IntelliSync |
| Abbott | Infinity | MRI compatibility |

Other Devices

| Company | Product | Application |
|---------|---------|--------------|
| Insightec | Exablate | Focused ultrasound |
| NeuroPace | RNS System | Responsive neurostimulation |

Company Profiles

Biogen

Headquarters: Cambridge, MA Focus: Alzheimer's, Parkinson's, ALS

Key products:

• Leqembi (lecanemab) - [Amyloid-beta](/proteins/amyloid-beta) antibody
• BIIB080 - Tau ASO
• BIIB113 - Synuclein antibody

Eli Lilly

Headquarters: Indianapolis, IN Focus: Alzheimer's, Parkinson's

Key products:

• Donanemab - Amyloid-beta antibody
• Remternetug - Amyloid-beta antibody
• Tirzepatide - GLP-1/GIP dual agonist

Roche

Headquarters: Basel, Switzerland Focus: Alzheimer's, Parkinson's

Key products:

• Gantenerumab - Amyloid-beta antibody
• Semorinemab - Tau antibody
• Prasinezumab - Alpha-synuclein antibody

Investment Landscape

Market Size

| Disease | Market (2024) | Projected (2030) |
|---------|---------------|------------------|
| Alzheimer's | $6B | $25B+ |
| Parkinson's | $5B | $15B+ |
| ALS | $1B | $3B+ |

Recent Funding

• 2024: $4.2B invested in neurodegenerative disease startups
• 2023: $3.8B invested
• Growth: 10%+ annually

Related Pages

• [Companies Index](/companies)
• [Company Rankings](/companies/rankings)
• [Investment](/investment)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

AI/ML Drug Discovery Companies

| Company | Approach | Focus Area | Notable |
|---------|----------|------------|---------|
| [Recursion Pharmaceuticals](/companies/recursion-pharmaceuticals) | High-throughput screening + ML | Oncology, Neuroscience | Phase 2 programs |
| [Insitro](/companies/insitro) | Machine learning + genetics | ALS, Alzheimer's | Genentech partnership |
| [Exscientia](/companies/exscientia) | Generative AI | CNS, Oncology | Clinical-stage AI company |
| [Healx](/companies/healx) | AI-powered rare disease | Rare diseases | AI platform |
| [Denali Therapeutics](/companies/denali) | Biologics + ML | Neuroscience | [LRRK2](/entities/lrrk2) program |

Topics

• [Companies Overview](/companies/overview) — This page
• [Companies Rankings](/companies/rankings) — Ranked list by research activity
• [Companies Dashboard](/companies/dashboard) — Data visualizations and metrics

Summary Statistics

• Total Pages: 196 Companies pages in this section
• Last Updated: This section is actively maintained

A-Z All Pages

• [4D Molecular Therapeutics](/companies/4d-molecular-therapeutics)
• [AB Science](/companies/ab-science)
• [AC Immune SA](/companies/ac-immune)
• [AD Pipeline](/companies/ad-pipeline)
• [AD Pipeline Companies](/companies/ad-pipeline-companies)
• [ALS Pipeline](/companies/als-pipeline)
• [ALS Pipeline Companies](/companies/als-pipeline-companies)
• [AbbVie](/companies/abbvie)
• [Abbott](/companies/abbott)
• [Abbott Laboratories](/companies/abbott-laboratories)
• [Acadia Pharmaceuticals](/companies/acadia-pharmaceuticals)
• [Acumen Pharmaceuticals](/companies/acumen-pharmaceuticals)
• [Acumen Pharmaceuticals, Inc.](/companies/acumen)
• [Ada Health](/companies/ada-health)
• [Alector, Inc.](/companies/alector)
• [Alnylam Pharmaceuticals](/companies/alnylam)
• [Alzheon](/companies/alzheon)
• [Amgen](/companies/amgen)
• [Amylyx Pharmaceuticals, Inc.](/companies/amylyx)
• [Anavex Life Sciences](/companies/anavex-life-sciences)
• [Annexon Biosciences](/companies/annexon)
• [Annovis Bio](/companies/annovis)
• [Annovis Bio, Inc.](/companies/annovis-bio)
• [Araclon Biotech S.L.](/companies/araclon)
• [Arbor Biotechnologies](/companies/arbor-biotechnologies)
• [Arcus Biosciences](/companies/arcus-biosciences)
• [AriBio](/companies/ari-bio)
• [Arrowhead Pharmaceuticals](/companies/arrowhead)
• [Aspen Neuroscience](/companies/aspen-neuroscience)
• [Astellas Pharma Inc.](/companies/astellas-pharma)

References